We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

The Role of Cytomegalovirus and Inflammation on Patient Symptoms and Outcomes in Ovarian Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03921658
Recruitment Status : Recruiting
First Posted : April 19, 2019
Last Update Posted : February 21, 2023
United States Department of Defense
Information provided by (Responsible Party):
University of Minnesota

Brief Summary:

Cytomegalovirus (CMV), a widely prevalent virus in the general US population, has been shown to be associated with increased inflammation and mortality. Previous small pilot studies have demonstrated that latent CMV may be reactivated during chemotherapy in cancer patients, and may be associated with unfavorable cancer outcomes such as fatigue and increased mortality.

The central research idea for this study, supported by previous preliminary data, is that CMV reactivation is an unrecognized complicating factor in the treatment of ovarian cancer that impacts patient outcomes. The overarching goals of this observational study are:

  • To assess how CMV infection is associated with ovarian cancer symptoms over the course of the disease and its treatment.
  • To describe the relationship between CMV reactivation in ovarian cancer patients, survival, fatigue, and other QOL outcomes, both cross-sectionally and longitudinally.

Condition or disease
Ovarian Cancer Fallopian Tube Cancer Primary Peritoneal Carcinoma

Layout table for study information
Study Type : Observational
Estimated Enrollment : 350 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Role of Cytomegalovirus and Inflammation on Patient Symptoms and Outcomes in Ovarian Cancer
Actual Study Start Date : October 22, 2019
Estimated Primary Completion Date : June 30, 2025
Estimated Study Completion Date : June 30, 2026

Cohort 1 - Cross-sectional (within 2 years of diagnosis)
Individuals diagnosed and treated for ovarian cancer in past two years, will complete 1 study measure
Cohort 2- Prospective (from diagnosis)
Individuals newly diagnosed with ovarian cancer, will complete 3 study measures (baseline/diagnosis, completion of chemotherapy, one year post-diagnosis)

Primary Outcome Measures :
  1. Cohort 1 - Cancer-related fatigue [ Time Frame: post treatment ]
    Cancer-related fatigue will be measured using the Fatigue Symptom Inventory. The scale is composed of 14 items (one is not scored). A total Disruption Index is calculated by summing items 5-11 (each item ranges from 0-10). A lower score indicates lower fatigue. Possible range is 0-70.

  2. Cohort 2 - Recurrence-free survival [ Time Frame: 3 years ]
    Time from diagnosis to first known recurrence or death, censored at least follow-up if recurrence free and alive

Biospecimen Retention:   Samples With DNA
Blood samples at up to 3 time points

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Individuals diagnosed and/or treated for ovarian/Fallopian tube/primary peritoneal cancer by physicians in the Gynecologic Oncology Clinic at the University of Minnesota

Inclusion Criteria:

  • Age ≥18
  • Ability to read and write in English
  • women with newly diagnosed with ovarian, primary peritoneal, or fallopian tube cancer
  • Treatment plan includes chemotherapy
  • Able to provide written voluntary consent before performance of any study related procedure.
  • Cohort 1 only: within 2 years of completing initial chemotherapy treatment
  • Cohort 2 only: prior to starting chemotherapy

Exclusion Criteria:

  • Inability to provide informed written consent
  • Previous exposure to chemotherapy
  • Life expectancy < 3 months or in hospice care or nursing home

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03921658

Layout table for location information
United States, Minnesota
University of Minnesota Recruiting
Minneapolis, Minnesota, United States, 55455
Contact: Rachel I Vogel, PhD    612-624-6928    isak0023@umn.edu   
Principal Investigator: Rachel I Vogel, PhD         
Sponsors and Collaborators
University of Minnesota
United States Department of Defense
Layout table for additonal information
Responsible Party: University of Minnesota
ClinicalTrials.gov Identifier: NCT03921658    
Other Study ID Numbers: 2019NTLS030
First Posted: April 19, 2019    Key Record Dates
Last Update Posted: February 21, 2023
Last Verified: February 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Fallopian Tube Neoplasms
Pathologic Processes
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Fallopian Tube Diseases